AVTX Exercise Disclosure
Sullivan Christopher Ryan · SEC Form 4 · Filed Sep 11, 2026
Exercise
Calculated transaction value
$81.89K
Sullivan Christopher Ryan Chief Financial Officer
AVTX
Avalo Therapeutics
AVTX
Transaction date
Sep 10, 2026
Public filing date
Sep 11, 2026
Filing lag
Filed 1 day later
AVTX daily price context
Close on/before transaction
$17.18
Sep 10, 2026
Close before public filing
$17.18
Sep 10, 2026
Return since public filing
-6.17%
Through Sep 11, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 10,185 shares @ $8.04
- SEC ownership
- Direct
- Transaction code
- M
- Form
- 4
- Filing identifier
- 0001810417-26-000021
Filing cohort
Transactions in this filing
Showing 3 of 3
Trades
3
Issuers
1
Estimated value
$261.34K
Buys / sales
0 / 1
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Avalo Therapeutics, Inc. AVTX Current | Exercise | Sep 10, 2026 | $81.89K |
| Avalo Therapeutics, Inc. AVTX | Sale | Sep 10, 2026 | $179.46K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Sep 10, 2026 | $0 |